H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Aclaris Therapeutics (ACRS) to $16 from $20 and keeps a Buy rating on the shares following the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics: Promising Pipeline and Strategic Developments Drive Buy Rating
- Aclaris Therapeutics Reports Q1 2025 Financial Results
- Aclaris Therapeutics price target lowered to $9 from $15 at Scotiabank
- Aclaris Therapeutics reports Q1 EPS (12c), consensus (12c)
- Aclaris Therapeutics appoints Hall as Chief Medical Officer